Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells
- PMID: 36740097
- PMCID: PMC9896859
- DOI: 10.1016/j.antiviral.2023.105550
Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells
Abstract
Host-oriented antiviral therapeutics are promising treatment options to combat COVID-19 and its emerging variants. However, relatively little is known about the cellular proteins hijacked by SARS-CoV-2 for its replication. Here we show that SARS-CoV-2 induces expression and cytoplasmic translocation of the nucleolar protein, nucleolin (NCL). NCL interacts with SARS-CoV-2 viral proteins and co-localizes with N-protein in the nucleolus and in stress granules. Knockdown of NCL decreases the stress granule component G3BP1, viral replication and improved survival of infected host cells. NCL mediates viral-induced apoptosis and stress response via p53. SARS-CoV-2 increases NCL expression and nucleolar size and number in lungs of infected hamsters. Inhibition of NCL with the aptamer AS-1411 decreases viral replication and apoptosis of infected cells. These results suggest nucleolin as a suitable target for anti-COVID therapies.
Keywords: Aptamer; COVID; Nucleolin; Nucleoprotein; SARS-CoV-2.
Copyright © 2023. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures







Similar articles
-
Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection.Antiviral Res. 2021 Jun;190:105064. doi: 10.1016/j.antiviral.2021.105064. Epub 2021 Mar 26. Antiviral Res. 2021. PMID: 33781803 Free PMC article.
-
SARS-CoV-2 N Protein Antagonizes Stress Granule Assembly and IFN Production by Interacting with G3BPs to Facilitate Viral Replication.J Virol. 2022 Jun 22;96(12):e0041222. doi: 10.1128/jvi.00412-22. Epub 2022 Jun 2. J Virol. 2022. PMID: 35652658 Free PMC article.
-
Beyond Stress Granules: G3BP1 and G3BP2 Redundantly Suppress SARS-CoV-2 Infection.Viruses. 2025 Jun 27;17(7):912. doi: 10.3390/v17070912. Viruses. 2025. PMID: 40733530 Free PMC article.
-
Intrinsic Factors Behind Long COVID: VI. Combined Impact of G3BPs and SARS-CoV-2 Nucleocapsid Protein on the Viral Persistence and Long COVID.J Cell Biochem. 2025 May;126(5):e70038. doi: 10.1002/jcb.70038. J Cell Biochem. 2025. PMID: 40415285 Review.
-
The roles of G3BP1 in human diseases (review).Gene. 2022 May 5;821:146294. doi: 10.1016/j.gene.2022.146294. Epub 2022 Feb 14. Gene. 2022. PMID: 35176431 Review.
Cited by
-
Pseudorabies virus IE180 protein hijacks G3BPs into the nucleus to inhibit stress granule formation.J Virol. 2025 Apr 15;99(4):e0208824. doi: 10.1128/jvi.02088-24. Epub 2025 Mar 27. J Virol. 2025. PMID: 40145738 Free PMC article.
-
New nucleolin-containing cytoplasmic bodies in an archamoebian protist Pelomyxa belevskii (Amoebozoa, Archamoebae, Pelobiontida).Protoplasma. 2025 May;262(3):695-706. doi: 10.1007/s00709-024-02017-x. Epub 2025 Jan 13. Protoplasma. 2025. PMID: 39805991
-
Bid Protein: A Participant in the Apoptotic Network with Roles in Viral Infections.Int J Mol Sci. 2025 Mar 7;26(6):2385. doi: 10.3390/ijms26062385. Int J Mol Sci. 2025. PMID: 40141030 Free PMC article. Review.
-
Hypoxia inducible factors inhibit respiratory syncytial virus infection by modulation of nucleolin expression.iScience. 2023 Dec 18;27(1):108763. doi: 10.1016/j.isci.2023.108763. eCollection 2024 Jan 19. iScience. 2023. PMID: 38261926 Free PMC article.
-
Integrated analysis of RNA-seq datasets reveals novel targets and regulators of COVID-19 severity.Life Sci Alliance. 2024 Jan 23;7(4):e202302358. doi: 10.26508/lsa.202302358. Print 2024 Apr. Life Sci Alliance. 2024. PMID: 38262689 Free PMC article.
References
-
- Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., Lopez de Castilla D., Finberg R.W., Dierberg K., Tapson V., Hsieh L., Patterson T.F., Paredes R., Sweeney D.A., Short W.R., Touloumi G., Lye D.C., Ohmagari N., Oh M.D., Ruiz-Palacios G.M., Benfield T., Fatkenheuer G., Kortepeter M.G., Atmar R.L., Creech C.B., Lundgren J., Babiker A.G., Pett S., Neaton J.D., Burgess T.H., Bonnett T., Green M., Makowski M., Osinusi A., Nayak S., Lane H.C., Members A.-S.G. Remdesivir for the treatment of covid-19 - final report. N. Engl. J. Med. 2020;383:1813–1826. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous